Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) is now available.
Hansoh Pharmaceutical Group Company Limited has announced the current composition of its board of directors, comprising three executive directors led by chairlady and chief executive officer Zhong Huijuan, and four independent non-executive directors. The company has also detailed the structure and membership of its five key board committees—Audit, Remuneration, Strategy and Development, Environmental, Social and Governance, and Nomination—clarifying the leadership roles and responsibilities within each, a move that underscores its emphasis on corporate governance, strategic oversight and ESG management for investors and other stakeholders.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$48.20 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company listed in Hong Kong that develops and manufactures prescription medicines, with a focus likely on innovative and generic drugs for the Chinese and broader Asian healthcare markets.
Average Trading Volume: 8,057,398
Technical Sentiment Signal: Buy
Current Market Cap: HK$226.6B
For a thorough assessment of 3692 stock, go to TipRanks’ Stock Analysis page.